Belimumab denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belimumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Belimumab on Medical-Necessity Grounds

Belimumab is a biologic approved for adults with active, autoantibody-positive systemic lupus erythematosus (SLE) and for active lupus nephritis. UnitedHealthcare's medical-necessity denials for belimumab typically occur when the submitted documentation does not clearly establish that the patient meets all of the plan's coverage criteria — such as confirmed autoantibody positivity, a minimum level of disease activity despite standard-of-care therapy, or inadequate response to specified prior treatments. These are documentation failures more often than true clinical ineligibility.

## Why This Denial Is Appealable

If your rheumatologist has determined that belimumab is medically necessary for your specific clinical situation, that professional judgment is supported by the FDA-approved prescribing label and applicable rheumatology guidelines. A denial based on missing or insufficiently detailed documentation is correctable. Gathering and presenting the right records in a structured format is the most effective appeal strategy.

## Federal Appeal Framework

• ACA §2719 external review: After exhausting UHC's internal appeal process, a binding IRO review is available. File within approximately four months of denial — confirm the exact deadline on your EOB.
• ERISA §503: Employer-plan members are entitled to the specific medical-necessity criteria used in the denial and a full-and-fair review.
• Expedited review: Available when SLE disease activity is severe, rapidly progressing, or involves major organ systems, and waiting for standard review timelines would seriously jeopardize health.

## Concrete Appeal Steps

1. Request the denial letter and UHC's full medical-necessity criteria for belimumab. 2. Identify each criterion the plan found unmet. 3. Work with the treating rheumatologist or nephrologist to gather documentation addressing every unmet criterion. 4. Submit the internal appeal within the EOB deadline (typically 180 days), with a structured response. 5. If the internal appeal is denied, escalate immediately to external IRO review.

## Documentation to Gather

• SLE diagnosis confirmation: rheumatology records, serology showing autoantibody positivity (ANA, anti-dsDNA, or anti-Smith, as documented in your chart).
• Disease-activity assessment: most recent clinical assessment of disease activity documented by your physician, including organ involvement and functional impact.
• Prior-therapy history: names of all conventional immunosuppressants and/or other agents tried, with start and stop dates, doses (from the chart), and documented outcomes or reasons for discontinuation.
• Prescriber medical-necessity letter: addresses each UHC criterion individually, references the FDA-approved prescribing label and the applicable ACR guideline, and explains why belimumab is the appropriate next step for this patient.

## Criteria-Mapping Structure

Copy each requirement from UHC's belimumab coverage policy verbatim into a table. In the adjacent column, cite the exact chart document, date, and clinical finding that satisfies each requirement. Submit this table as the centerpiece of your appeal. IRO reviewers regularly reverse medical-necessity denials when presented with this format because it demonstrates complete, organized clinical justification.